Omega-3-acid ethyl esters
- Generic Name
- Omega-3-acid ethyl esters
- Brand Names
- Lovaza, Omtryg
- Drug Type
- Small Molecule
- CAS Number
- 308081-97-2
- Unique Ingredient Identifier
- D87YGH4Z0Q
- Background
Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia. Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza.
- Indication
Omega-3-Acid Ethyl Esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG).
- Associated Conditions
- Severe Hypertriglyceridemia (sHTG)
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
- First Posted Date
- 2009-12-31
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Tufts University
- Target Recruit Count
- 129
- Registration Number
- NCT01041521
- Locations
- 🇺🇸
Tufts University School of Medicine, Boston, Massachusetts, United States
Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 35
- Registration Number
- NCT01001767
- Locations
- 🇺🇸
University Hospitals of Cleveland Case Medical Center, Cleveland, Ohio, United States
Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Sanford Research
- Target Recruit Count
- 15
- Registration Number
- NCT00959842
- Locations
- 🇺🇸
Sanford Research/USD, Sioux Falls, South Dakota, United States
The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 58
- Registration Number
- NCT00944229
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2010-06-10
- Lead Sponsor
- Huntington Medical Research Institutes
- Target Recruit Count
- 40
- Registration Number
- NCT00941642
- Locations
- 🇺🇸
HMRI - Liver Center, Pasadena, California, United States
Triglyceride Lowering Study
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Jewish Hospital, Cincinnati, Ohio
- Target Recruit Count
- 25
- Registration Number
- NCT00934219
- Locations
- 🇺🇸
Jewish Hospital Cholesterol Center, Cincinnati, Ohio, United States
Fish Oil Study for High Triglyceride Levels in Children
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Babu Balagopal
- Target Recruit Count
- 42
- Registration Number
- NCT00915902
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸A. I. duPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸Thomas Jefferon University, Philadelphia, Pennsylvania, United States
Pulmonary Vein Isolation Outcomes With Fish Oils
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- St. Luke's-Roosevelt Hospital Center
- Registration Number
- NCT00841451
- Locations
- 🇺🇸
The Valley Hospital, Ridgewood, New Jersey, United States
🇺🇸University Medical Practice Associates 425 West 59th St. #9C, New York, New York, United States
🇺🇸St.Luke's Hospital 1111 Amsterdam Ave. 3rd Floor Cardiology, New York, New York, United States
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
- Conditions
- High TriglyceridesSchizophreniaHypercholesterolemiaBipolar DisorderSchizoaffective Disorder
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 65
- Registration Number
- NCT00833976
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers
- Conditions
- Muscle DamageMuscle Inflammation
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2012-09-05
- Lead Sponsor
- Western Michigan University
- Target Recruit Count
- 20
- Registration Number
- NCT00805870
- Locations
- 🇺🇸
Western Michigan University, Kalamazoo, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.